AI tool for thymus tumors
Part of Blood & lymphatic, Cancer clinical trials.
This study is using an artificial intelligence tool to help doctors better predict how thymus tumors (thymoma and thymic carcinoma) will behave. It may help guide decisions about treatment and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of one of these thymus tumor types: Thymoma A, AB, B1, B2, B3, or Thymic Carcinoma.
- The diagnosis must have been made with less than 70% agreement among pathologists (meaning there was some uncertainty).
- For part of the study, you must have information about whether the tumor came back (recurred) within 5 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an artificial intelligence (AI) helper that assists doctors in managing thyroid cancer. It aims to see if the tool can improve care for patients like you.
This trial uses an artificial intelligence system to help doctors more accurately diagnose and predict the outcome of breast phyllodes tumors, which are rare breast growths. It aims to improve how these tumors are identified and managed.
This study uses artificial intelligence to analyze electronic health records (including medical history, lab results, and imaging data) to improve cancer diagnosis and prediction. It aims to help identify cancer earlier and more accurately, potentially leading to better treatment outcomes.
This trial tests an artificial intelligence (AI) system that helps doctors decide if a skin lesion might be cancer. If you are seeing your primary care doctor about a mole or spot that concerns them or you, this study might be for you.
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
This study is testing whether an artificial intelligence system can find very small amounts of leftover cancer (minimal residual disease) after treatment for rectal or esophageal cancer. If successful, this could help doctors detect a relapse earlier than current methods.
Hear when a new Thymic Epithelial Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.